ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,559,761 | +3.1% | 16,657 | -1.7% | 2.01% | +10.5% |
| Q2 2023 | $1,512,520 | +32.4% | 16,947 | +59.1% | 1.82% | +15.1% |
| Q1 2023 | $1,142,107 | -58.2% | 10,652 | -52.3% | 1.58% | -39.6% |
| Q4 2022 | $2,729,239 | -9.3% | 22,347 | -23.3% | 2.62% | -9.5% |
| Q3 2022 | $3,010,000 | +42.9% | 29,146 | +28.6% | 2.90% | +26.3% |
| Q2 2022 | $2,106,000 | -52.1% | 22,659 | -39.6% | 2.29% | -25.0% |
| Q1 2022 | $4,401,000 | -23.4% | 37,501 | -12.2% | 3.06% | +10.9% |
| Q4 2021 | $5,746,000 | +55.1% | 42,712 | +83.8% | 2.76% | +67.8% |
| Q3 2021 | $3,705,000 | +62.1% | 23,242 | +33.8% | 1.64% | +56.0% |
| Q2 2021 | $2,285,000 | +5.7% | 17,370 | +3.6% | 1.05% | -17.5% |
| Q1 2021 | $2,161,000 | +6.1% | 16,764 | +37.3% | 1.28% | -17.7% |
| Q4 2020 | $2,037,000 | – | 12,212 | – | 1.55% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |